Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Novel Reagent Enhances Specificity of IgM-based Immunodiagnostic Assays

By LabMedica International staff writers
Posted on 19 Apr 2012
A new absorbent reagent specifically designed for use in conjunction with immunodiagnostic assays is distinctively formulated to remove both IgG and Rheumatoid Factor (RF)-IgM molecules from human serum.

Developed by Binding SIte (San Diego, CA, USA), the “RF/IgG Absorbent Reagent” demonstrates outstanding performance characteristics in routine forms of use. More...
In principle, the reagent effectively prevents these IgG and RF-IgM bodily components from nonspecific binding within the test sample. This eliminates certain interference effects found with some immunodiagnostic assays, which are looking to determine quantitatively human antigen-specific IgM immunoglobulin concentrations, as found in various diagnostic disease states. As such, the RF/IgG Absorbent Reagent serves to enhance overall specificity by reducing both the amount of false positive test results from native IgG components and the amount of false negative test results from native RF-IgM components.

Binding Site’s new RF/IgG Absorbent Reagent is available as a ready-to-use, liquid stable product and is offered in a number of convenient, operator-oriented packaging configurations, including bulk-sized formats.

Related Links:
Binding Site



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.